Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2019.1640348
Abstract: Abstract Background: Tildrakizumab is a high-affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody approved for moderate-to-severe plaque psoriasis. Objectives: This analysis examined whether tildrakizumab’s week-28 efficacy can be sustained or improved to week 52. Methods: Psoriasis… read more here.
Keywords: week; pasi responses; week pasi; tildrakizumab ... See more keywords
Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin‐23/interleukin‐17 pathway in the pathogenesis of lichen planus
Sign Up to like & getrecommendations! Published in 2019 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13183
Abstract: We report on a 59-year-old lady with a nine-month history of biopsy-proven, severe erosive oral lichen planus (OLP) that was refractory to multiple treatments, who experienced significant clinical improvement after three doses of the anti-interleukin-23… read more here.
Keywords: oral lichen; lichen; erosive oral; tildrakizumab ... See more keywords
Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13216
Abstract: Dear Editor, We report on a 40-year-old man with psoriatic nail dystrophy and psoriatic arthritis who had an excellent clinical response to the anti-interleukin-23 (IL-23) monoclonal antibody tildrakizumab. His past medical history included bipolar disorder,… read more here.
Keywords: psoriatic arthritis; treatment; nail; tildrakizumab ... See more keywords
Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15488
Abstract: New biologic agents targeting interleukin (IL)23/T‐helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected… read more here.
Keywords: tildrakizumab; real life; week; psoriasis ... See more keywords